PRMT5 and prostate carcinoma: We also determined that nanocomplex (NC) delivery of a competitive peptide to block interaction of FUBP1 with PRMT5 is a potential therapeutic strategy to treat prostate cancer by preventing PRMT5-mediated FUBP1 methylation.